Timing impact on the initiation of pirfenidone therapy on idiopathic pulmonary fibrosis disease progression DOI

Basma M E Mohamed,

Mohamed E. A. Abdelrahim

World Journal of Clinical Cases, Год журнала: 2024, Номер 12(32), С. 6538 - 6542

Опубликована: Сен. 23, 2024

In this editorial, we comment on the article by Lei et al, with a specific focus timing of initiation antifibrotic agent pirfenidone (PFD) in management idiopathic pulmonary fibrosis (IPF) and its impact lung function IPF patients. PFD is an that widely used both early advanced stages. It inhibits various pathways has antifibrotic, anti-inflammatory, antioxidant properties. Despite dosage lowering, slowed progression maintained functional capacity. The 6-min walk distance test indicated patients tolerated adverse events well, significantly reduced incidence episodes death. Even when single disease-progression event occurred, continuing treatment had benefits.

Язык: Английский

Decoding the role of extracellular vesicles in pathogenesis of cystic fibrosis DOI Creative Commons

P.S. Kalsi,

Nikhil Gupta, Gitanjali Goyal

и другие.

Molecular and Cellular Pediatrics, Год журнала: 2025, Номер 12(1)

Опубликована: Апрель 21, 2025

Язык: Английский

Процитировано

0
Timing impact on the initiation of pirfenidone therapy on idiopathic pulmonary fibrosis disease progression DOI

Basma M E Mohamed,

Mohamed E. A. Abdelrahim

World Journal of Clinical Cases, Год журнала: 2024, Номер 12(32), С. 6538 - 6542

Опубликована: Сен. 23, 2024

In this editorial, we comment on the article by Lei et al, with a specific focus timing of initiation antifibrotic agent pirfenidone (PFD) in management idiopathic pulmonary fibrosis (IPF) and its impact lung function IPF patients. PFD is an that widely used both early advanced stages. It inhibits various pathways has antifibrotic, anti-inflammatory, antioxidant properties. Despite dosage lowering, slowed progression maintained functional capacity. The 6-min walk distance test indicated patients tolerated adverse events well, significantly reduced incidence episodes death. Even when single disease-progression event occurred, continuing treatment had benefits.

Язык: Английский

Процитировано

1